TGFBR1 inhibition for GATA4-deficient lung cancer

INDICATION: Non-small cell lung cancer (NSCLC)

Cell culture and mouse studies suggest inhibiting TGFBR1 could help treat GATA4-deficient NSCLC. In a human GATA4-deficient NSCLC cell line, a tool compound TGFBR1 inhibitor decreased growth compared with vehicle. In that and another human GATA4-deficient NSCLC cell line, the TGFBR1 inhibitor plus the MEK inhibitor Mekinist trametinib decreased growth compared with either agent alone. In a patient-derived xenograft (PDX) mouse model of GATA4-deficient NSCLC, the TGFBR1 inhibitor plus cisplatin decreased growth. Next steps could include testing TGFBR1 inhibitors in combination with other therapies in PDX models...